van de Wetering-van Dongen Veerle A, Nijkrake Maarten J, van der Wees Philip J, IntHout Joanna, Darweesh S K L, Bloem Bastiaan R, Kalf Johanna G
Department of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Center, Donders Institute for Brain, Cognition and Behaviour, 6500 HB, P.O. Box 9101 (internal code 898), Nijmegen, The Netherlands.
Department of Rehabilitation and IQ Healthcare, Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, The Netherlands.
J Neurol. 2025 Mar 22;272(4):283. doi: 10.1007/s00415-025-13008-0.
The prevalence of respiratory dysfunction in PD is unknown and a better understanding of determinants contributing to respiratory dysfunction is important to facilitate early recognition and treatment.
To examine the prevalence and determinants of self-reported symptoms of respiratory dysfunction among people with PD.
In a cross-sectional study, we administered a self-completed questionnaire among a sample of 939 persons with PD. Respiratory dysfunction was defined as experiencing at least one of the following symptoms: breathing difficulties, breathlessness/shortness of breath, tightening of the chest, frequent throat clearing, frequent coughing, or coughing difficulties. A principal component analysis (PCA) was used to define composite constructs of respiratory dysfunction. The association with participant-reported determinants was assessed using multivariable logistic regression models (with adjustment for pulmonary diseases and COVID-19 symptoms).
The overall prevalence rate of respiratory dysfunction was 44% in persons with PD (42% after excluding pulmonary diseases or COVID-19). The PCA resulted in two constructs of respiratory dysfunction: 'dyspnea' and 'dystussia' (an impaired cough response), which together explained 68% of the total variance. Female sex (OR = 1.39), higher BMI kg/m (OR = 1.04), longer disease duration (OR = 1.35), greater self-reported rigidity (OR = 1.16), previous pulmonary disease(s) (OR = 7.12), and anxiety (OR = 1.04) were independently associated with 'dyspnea'. Pulmonary disease(s) (OR = 1.81), COVID-19 symptoms (OR = 2.20), swallowing complaints (OR = 1.48), and speech complaints (OR = 1.02) were independently associated with 'dystussia'.
Dyspnea and dystussia are common manifestations of respiratory dysfunction among people with PD and deserves more awareness in clinical practice. A proactive screening for the determinants of dyspnea and dystussia may contribute to earlier recognition and treatment of respiratory dysfunction.
帕金森病(PD)患者呼吸功能障碍的患病率尚不清楚,更好地了解导致呼吸功能障碍的决定因素对于促进早期识别和治疗至关重要。
研究帕金森病患者自我报告的呼吸功能障碍症状的患病率及决定因素。
在一项横断面研究中,我们对939名帕金森病患者样本进行了自我填写问卷调查。呼吸功能障碍定义为出现以下至少一种症状:呼吸困难、气促/呼吸急促、胸部紧绷、频繁清嗓、频繁咳嗽或咳嗽困难。采用主成分分析(PCA)来定义呼吸功能障碍的综合结构。使用多变量逻辑回归模型评估与参与者报告的决定因素之间的关联(对肺部疾病和新冠病毒病症状进行调整)。
帕金森病患者呼吸功能障碍的总体患病率为44%(排除肺部疾病或新冠病毒病后为42%)。主成分分析得出呼吸功能障碍的两个结构:“呼吸困难”和“咳嗽功能障碍”(咳嗽反应受损),它们共同解释了总方差的68%。女性(比值比[OR]=1.39)、较高的体重指数(kg/m)(OR=1.04)、较长的病程(OR=1.35)、自我报告的较高强直程度(OR=1.16)、既往肺部疾病(OR=7.12)和焦虑(OR=1.04)与“呼吸困难”独立相关。肺部疾病(OR=1.81)、新冠病毒病症状(OR=2.20)、吞咽主诉(OR=1.48)和言语主诉(OR=1.02)与“咳嗽功能障碍”独立相关。
呼吸困难和咳嗽功能障碍是帕金森病患者呼吸功能障碍的常见表现,在临床实践中应提高认识。对呼吸困难和咳嗽功能障碍的决定因素进行积极筛查可能有助于呼吸功能障碍的早期识别和治疗。